AHA

This channel contains news about the American Heart Association (AHA), including coverage of its annual meeting and guidelines. AHA is a leading resource for cardiology information, both consumer and professional.  

COVID-19 cardiology related content continues to be among the top performers on the DAIC website in November 2020. TAVR also topped headlines with Boston Scientific taking its Lotus valve off the market and a review of TAVR registry data showing it is now the dominant method of aortic valve replacement in the United States. #DAIC

COVID-19 cardiology related content continues to be among the top performers on the DAIC website in November 2020. TAVR also topped headlines with Boston Scientific taking its Lotus valve off the market and a review of TAVR registry data showing it is now the dominant method of aortic valve replacement in the United States.

Feature | Cardiovascular Business | December 01, 2020 | Dave Fornell, Editor
Most Popular Cardiology Technology Content in November 2020
December 1, 2020 — Here is the list of the most popular content on the Diagnostic and Interventional Cardiology (DAIC)...
read more
One-year results off the PIONEER III study comparing the safety and efficacy of the Supreme HT drug-eluting stent (DES), to the Xience or Promus Durable Polymer DES showed it was equivalent in clinical performance to the market-leading DES. The results were presented at the 2020 American Heart Association (AHA) Scientific Session. #AHA2020 #AHA20 #AHA

One-year results off the PIONEER III study comparing the safety and efficacy of the Supreme HT drug-eluting stent (DES), to the Xience or Promus Durable Polymer DES showed it was equivalent in clinical performance to the market-leading DES. The results were presented at the 2020 American Heart Association (AHA) Scientific Session.

News | Stents | November 24, 2020
Biodegradable Drug Eluting Coronary Stent Noninferior to Xience or Promus Durable Polymer Stents
November 24, 2020 — One-year results off the PIONEER III study comparing the safety and efficacy of the Supreme HT (...
read more
Videos | Coronavirus (COVID-19) | November 18, 2020
VIDEO: Lingering Myocardial Involvement After COVID-19 Infection
Aaron Baggish, M.D., director of the cardiovascular performance program, Massachusetts General Hospital. He was on a...
read more
Results from study of more than 14,000 patients across the United States show the heavy impact of cardiac disease on hospitalized COVID patients. COVID-19 patients with cardiovascular diseases have in-hospital mortality rates of between 25 to 38 percent. #AHA #AHA20 #AHA2020 #COVID19 #Coronavirus #SARSCoV2

Results from study of more than 14,000 patients across the United States show the heavy impact of cardiac disease on hospitalized COVID patients. COVID-19 patients with cardiovascular diseases have in-hospital mortality rates of between 25 to 38 percent. 

News | Coronavirus (COVID-19) | November 18, 2020 | Dave Fornell, Editor
COVID-19 Patients With Cardiovascular Disease Have In-hospital Mortality Rates of 25 to 38 Percent
November 18, 2020 — A late-breaking study at the 2020 American Heart Association (AHA) Scientific Sessions showed...
read more
RIVER trial is the largest study assessing the efficacy and safety of the anticoagulant rivaroxaban in patients with an artificial mitral valve to correct an irregular heart rhythm
News | November 18, 2020
Rivaroxaban is Comparable to Warfarin for Bioprosthetic Mitral Valves and AF
November 18, 2020 — The primary results from the RIVER Trial, Rivaroxaban for Valvular Heart disease and Atrial...
read more
Black patient being tested for COVID-19 using a nasal swab PCR test. black adults with COVID-19 were far more likely to be hospitalized than their white counterparts according to data from the AHA COVID-19 Cardiovascular Disease Registry. #AHA #AHA20 #AHA2020 #COVID19 #SARSCoV2

Black patient being tested for COVID-19 using a nasal swab PCR test. Black adults with COVID-19 were far more likely to be hospitalized than their white counterparts according to new data from the AHA COVID-19 Cardiovascular Disease Registry. 

Feature | Coronavirus (COVID-19) | November 18, 2020
COVID-19 Cardiovascular Registry Details Disparities Among Hospitalized Patients
November 18, 2020 -- A new American Heart Association (AHA) collaborative model for COVID-19 (SARS-CoV-2) research,...
read more
Videos | Atrial Fibrillation | November 18, 2020
VIDEO: Screening for Atrial Fibrillation Using Single Lead ECG in the VITAL-AF Trial
Steven Lubitz, M.D., MPH, cardiac electrophysiologist, Massachusetts General Hospital, presented the late-breaking...
read more
Women’s Heart Attack Research Program (HARP) shows combining OCT and cardiac MRI can detect the underlying cause of heart attack in women who did not have blocked arteries

The Women’s Heart Attack Research Program (HARP) study shows combining OCT and cardiac MRI can help detect the underlying cause of heart attacks in women who did not have blocked arteries.

News | Cardiac Imaging | November 17, 2020
OCT Combined with MRI Can Identify Cause of Unexplained Heart Attacks in Women
November 17, 2020 — Diagnostic imaging techniques were able to find the underlying cause of heart attack in many women...
read more
Omega-3 fish oil supplements did not help patients after a heart attack in AHA 2020 study. #AHA #AHA20 #AHA2020. Getty Images

Omega-3 fish oil supplements did not help patients after a heart attack. Getty Images

News | Pharmaceuticals | November 17, 2020
Omega-3s Do Not Reduce Cardiac Events in Recent Heart Attack Survivors
November 17, 2020 — A daily dose of omega-3 fatty acids did not reduce the risk of cardiac events, including secondary...
read more
Among high-risk, chronic, coronary patients who undergo angioplasty, there were no additional benefits from ticagrelor compared to the current standard of care clopidogrel. #AHA #AHA20 #AHA2020
News | Cath Lab | November 16, 2020
Ticagrelor Not Superior to Clopidogrel in Reducing Heart Attacks During PCI
November 16, 2020 — The use of the more potent antiplatelet medication ticagrelor (Brilinta) was not superior to...
read more
The Medtronic SEEQ mobile cardiac telemetry system, pictured here, and the Icentia CardioSTAT cardiac rhythm monitoring device both found in reased rates of post-operative atrial fibrillation in the SEARCH-AF trial presented at the American Heart Association annual meeting. #AHA #AHA20 #AHA2020

The Medtronic SEEQ mobile cardiac telemetry system, pictured here, and the Icentia CardioSTAT cardiac rhythm monitoring device both found in reased rates of post-operative atrial fibrillation in the SEARCH-AF trial presented at the American Heart Association annual meeting.

News | Atrial Fibrillation | November 16, 2020
Patients at Risk of AF May Need Extra Monitoring After Heart Surgery
November 16, 2020 — Atrial fibrillation (AF), an irregular heartbeat that can increase the likelihood of stroke, was...
read more
The Medtronic Arctic Front cryoballoon balloon was used a a front-line treatment of AF in the EARLY-AF trial. It was found to be better than anti-arrhythmic drugs in preventing the recurrence of abnormal heart rhythm (atrial tachyarrhythmia, atrial fibrillation), and improve patient well-being.  #AHA #AHA2020 #AHA20

The Medtronic Arctic Front cryoballoon balloon was used a a front-line treatment of AF in the EARLY-AF trial. It was found to be better than anti-arrhythmic drugs in preventing the recurrence of abnormal heart rhythm (atrial tachyarrhythmia, atrial fibrillation), and improve patient well-being.  

News | Atrial Fibrillation | November 16, 2020
Early Invasive Intervention for Atrial Fibrillation May Improve Patient Outcomes and Provide a Better Quality of Life
November 16, 2020 – Doctors from the Montreal Heart Institute (MHI) presented new data that shows catheter ablation as...
read more
The AHA 2020 late-breaking SAMSON Trial found side effects reported from statins are real, but appear due to the psychological rather than the pharmacological effects of the cholesterol lowering drugs. #AHA20 #AHA2020

The AHA 2020 late-breaking SAMSON Trial found side effects reported from statins are real, but appear due to the psychological rather than the pharmacological effects of the cholesterol  lowering drugs.

News | Pharmaceuticals | November 16, 2020
Side Effects Attributed to Statins Same for Those Taking a Placebo
November 16, 2020 — Among patients who stopped taking their cholesterol-lowering statin medication due to side effects...
read more
New Novartis Data for Inclisiran Shows Effective and Sustained LDL-C Reduction at 17 Regardless of Age or Gender. Getty Images.

Getty Images

News | Pharmaceuticals | November 16, 2020
New Novartis Data for Inclisiran Shows Effective and Sustained LDL-C Reduction at 17 Regardless of Age or Gender
November 16, 2020 — Novartis announced results from two pooled post-hoc analyses of Phase III ORION-9, -10 and -11...
read more
The American Heart Association, AHA, late-breaking sessions, trials, studies. #AHA #AHA20 #AHA2020
Feature | AHA | November 20, 2020 | Dave Fornell, Editor
American Heart Association 2020 Late-breaking Trial Presentations 
Here is a list of the American Heart Association (AHA) late-breaking clinical trial presentations at the 2020 Virtual...
read more
© Copyright Wainscot Media. All Rights Reserved.